A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression: Protocol MK7902-011-00

  • Zhang, Alison (Primary Chief Investigator)
  • Butala, Radhika, (Clinical Trial Unit Staff)
  • Chapman, Nicola, (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymLEAP-011
StatusActive
Effective start/end date13/09/196/06/24